Contact Congress about S. 822: Scientific EXPERT Act of 2025

Experts, patients, drug makers, and FDA staff would meet about rare-disease drug research at least four times a year. The FDA would later explain how it used their advice.

Modern Action explains what the legislation does, helps you choose whether to support, oppose, or ask for changes, and drafts a message tied to the bill, your stance, and the elected officials who can act on it.

Scientific EXPERT Act of 2025 is a Senate bill committee Action. The latest recorded action: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Latest action on S. 822: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.

Who this affects: People with rare diseases and groups that represent them would gain a formal place in talks about drug research. Drug makers and researchers could receive clearer public information about study methods. FDA staff would have new meeting, review, and reporting duties. The Reagan-Udall Foundation would organize the program.

Why this matters: Rare-disease drug studies are often difficult because patient groups are small and key science questions may remain unsettled. These meetings could make the FDA's thinking clearer to patients and drug makers. Public records could also give smaller groups access to information often shared in private talks. Still, the bill does not change approval standards. Its effect would depend on how well the meetings work and how the FDA uses their advice.

Key provisions in S. 822

• The Health and Human Services Secretary would have to create and run a formal meeting program. Outside experts would lead talks about drugs for rare diseases.
• The bill names the Reagan-Udall Foundation for the FDA as the official outside organizer. The legal term is “qualified third-party convenor.”
• The Foundation must hold at least four meetings each year. Each meeting must cover a different rare disease or disease group.
• A permanent steering committee would review suggested topics and recommend which ones get meetings. It must consider unmet medical needs and whether a meeting could help many people.
• FDA staff from the right drug review office must take part in every meeting.

How Modern Action helps you take action on S. 822

You do not have to start with a blank letter. Modern Action turns the bill, your position, and the relevant congressional context into a message you can edit and send. The goal is to make contacting Congress clear, specific, and useful without forcing you to parse bill text or figure out the right office on your own.

Questions people ask about S. 822

What is S. 822?

Experts, patients, drug makers, and FDA staff would meet about rare-disease drug research at least four times a year. The FDA would later explain how it used their advice.

How do I support or oppose S. 822?

Choose support, oppose, or ask for changes on Modern Action. The action flow drafts the message for you and keeps the wording tied to this bill.

Who should I contact about S. 822?

Modern Action uses your location to route the action to the congressional offices relevant to the bill and your representation.

How does Modern Action help me act on S. 822?

Modern Action gives you bill-specific context, lets you choose support, opposition, or changes, and drafts a message from your position and reasons.